Study of Vitiligo Repigmentation with Systemic and Topical Unani Formulations - An Open Label Clinical Study

Abstract

Vitiligo affects about 0.1–8% of the world population [1]. Because of cosmetic problems, Vitiligo needs more attention because it leads to social isolation and psychological discomfort [2]. The efficacy of compound Unani formulations UNIM 004 and UNIM 005 (coded) both systemic and topical effects were studied in an open label study. 2020 patients were treated and evaluated for their regimentation pattern in relation to different clinical types of Vitiligo as non dermatomal, acrofacial and mixed Vitiligo (Generalized), segmental, mucosal and focal Vitiligo (localized) and were evaluated initially after 3 months and subsequently once every 2 months for a total period of 9 months. Response to the treatment was recorded as follicular and peri-lesional repigmentation in relation to age, duration of disease, extension and distribution of lesions. The mixed and nondermatomal Vitiligo responded well 41±19 and 39±18 mean percent of re-pigmentation respectively (p<0.001) than acrofacial Vitiligo 35±19 among generalized type, whereas focal and segmental Vitiligo responded better i.e. 42±23 and 36±18 mean percent of re-pigmentation respectively which is better than mucosal Vitiligo 34±19 among localized types (p<0.05). Acknowledgments: Thanks to the clinical Research Team of the Central Research Institute of Unani medicine, Hyderabad for conducting clinical trials on Unani Medicines for Vitiligo management. Reference: [1] Alikhan A, Felsten LM, et al. (2011)J Am Acad Dermatol 65(3): 473–91. [2] Ongenae K, Beelaert L, et al. (2006)J Eur Acad Dermatol Venereol 20(1): 1–8.